BR0309819A - Formulações farmacêuticas - Google Patents

Formulações farmacêuticas

Info

Publication number
BR0309819A
BR0309819A BR0309819-2A BR0309819A BR0309819A BR 0309819 A BR0309819 A BR 0309819A BR 0309819 A BR0309819 A BR 0309819A BR 0309819 A BR0309819 A BR 0309819A
Authority
BR
Brazil
Prior art keywords
desmopressin
formulated
pharmaceutical formulations
manner
water
Prior art date
Application number
BR0309819-2A
Other languages
English (en)
Inventor
Anders Nilsson
Hans Lindner
Jorgen Wittendorff
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0210397.6A external-priority patent/GB0210397D0/en
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR0309819A publication Critical patent/BR0309819A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES FARMACêUTICA". A presente invenção refere-se a boa biodisponibilidade de desmopressina que pode ser obtida por meio de uma forma de dosagem farmacêutica orodispersível. Formas de dosagem preferidas compreendem desmopressina e uma rede de matriz aberta que é um veículo inerte solúvel em água ou passível de dispersão em água. Desmopressina formulada dessa maneira é útil para retardo miccional, ou para o tratamento ou prevenção de incontinência, enurese noturna primária (PNE), noctúria e/ou diabetes insípida central. Peptídeos diferentes de desmopressina podem também ser formulados dessa maneira.
BR0309819-2A 2002-05-07 2003-05-07 Formulações farmacêuticas BR0309819A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210397.6A GB0210397D0 (en) 2002-05-07 2002-05-07 Pharmaceutical formulations
PCT/IB2002/004036 WO2003094885A1 (en) 2002-05-07 2002-09-20 Sublingual pharmaceutical formulation of desmopressin
PCT/IB2003/002368 WO2003094886A2 (en) 2002-05-07 2003-05-07 Desmopressin in an orodispersible dosage form

Publications (1)

Publication Number Publication Date
BR0309819A true BR0309819A (pt) 2005-03-01

Family

ID=29422105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309819-2A BR0309819A (pt) 2002-05-07 2003-05-07 Formulações farmacêuticas

Country Status (10)

Country Link
JP (1) JP2006502972A (pt)
AU (1) AU2003233118B8 (pt)
BR (1) BR0309819A (pt)
CA (1) CA2484724C (pt)
DE (2) DE60307082D1 (pt)
HR (1) HRP20041152B1 (pt)
NO (1) NO335167B1 (pt)
NZ (1) NZ535861A (pt)
PT (1) PT1501534E (pt)
WO (1) WO2003094886A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
PT1500390E (pt) 2003-07-25 2005-10-31 Ferring Bv Composicao farmaceutica como forma de dosagem solida e metodo de producao
EP2322195A2 (en) * 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE60305043T2 (de) 2003-11-13 2006-11-30 Ferring B.V. Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
CA2490601C (en) * 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
SI1550439T1 (sl) * 2003-12-29 2006-08-31 Ferring Bv Postopek za pripravo trdne dozirne oblike dezmopresina
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
GB0406048D0 (en) * 2004-03-18 2004-04-21 Ardana Bioscience Ltd Drug formulations
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
CA2584456C (en) * 2006-03-02 2008-07-22 Ferring International Center S.A. Composition comprising desmopressin
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
NZ582586A (en) 2007-07-21 2011-12-22 Albany Molecular Res Inc 5-pyridinone substituted indazoles
KR101522747B1 (ko) * 2007-08-06 2015-05-26 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
CN102026970B (zh) 2007-11-21 2013-07-31 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4抑制剂
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CA2724653A1 (en) * 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2389383B1 (en) 2009-01-26 2019-04-24 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
TWI468157B (zh) * 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
TWI471127B (zh) * 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
PT2442821T (pt) 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
WO2011008572A2 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
TWI498132B (zh) * 2010-03-29 2015-09-01 Ferring Bv 快速溶解之藥學組成物（二）
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR083361A1 (es) * 2010-10-08 2013-02-21 Scherer Technologies Inc R P Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
JP2011116764A (ja) * 2011-02-08 2011-06-16 Fine Seymour H 低用量デスモプレシンを含有する医薬組成物
BR112014005134A2 (pt) 2011-09-16 2017-04-18 Ferring Bv composição farmacêutica de dissolução rápida
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CN103993061B (zh) * 2014-05-20 2018-03-23 海南美合泰生物科技有限公司 一种鱼胶原蛋白的生产方法
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
JP6341777B2 (ja) * 2014-06-30 2018-06-13 リプリーズ バイオファーマシューティクス，エルエルシー 低用量デスモプレシンを含有する医薬組成物
CA3046725A1 (en) 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
DE102017104472A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
JP3253127B2 (ja) * 1991-06-07 2002-02-04 帝國製薬株式会社 生理活性ポリペプチド含有製剤
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5298256A (en) * 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
EP1146800A1 (en) * 1999-01-27 2001-10-24 Spenco Medical Corporation Therapeutic magnetic insoles
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions

Also Published As

Publication number Publication date
NO335167B1 (no) 2014-10-06
HRP20041152B1 (en) 2008-01-31
PT1501534E (pt) 2006-09-29
CA2484724C (en) 2007-01-16
WO2003094886A3 (en) 2004-07-22
DE60307082T2 (de) 2007-01-18
DE60307082T4 (de) 2015-04-30
HRP20041152A2 (en) 2005-04-30
NZ535861A (en) 2006-11-30
AU2003233118A1 (en) 2003-11-11
DE60307082D1 (de) 2006-09-07
JP2006502972A (ja) 2006-01-26
WO2003094886A2 (en) 2003-11-20
AU2003233118B2 (en) 2006-10-26
CA2484724A1 (en) 2003-11-20
AU2003233118B8 (en) 2009-07-30
NO20045345L (no) 2005-02-07

Similar Documents

Publication Publication Date Title
BR0309819A (pt) Formulações farmacêuticas
MY131153A (en) Desmopressin in an orodispersible dosage form
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition
BR0208183A (pt) Peptìdeo modificado por wt1
BR0212921A (pt) Composição farmacêutica com base em fondant
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
BR9908438A (pt) Tabletes de desintegração rápida
BR0203172A (pt) Agentes terapêuticos para acondroplasia
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
ATE344022T1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
ES2319886T3 (es) Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
BR0307516A (pt) Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
ATE447858T1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
HRP20050439B1 (en) New use of dextran sulfate
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
AU2003255820A1 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
MY126117A (en) Pharmaceutical compositions
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
DK1000059T3 (da) Tricycliske vasopressin-agonister

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/00, 9/20; A61P 7/12

Ipc: A61K 9/00 (2011.01), A61K 9/20 (2011.01), A61P 7/1

B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B12B Appeal: appeal against refusal